Evaluation of Guanfacine as a Potential Medication for Alcohol Use Disorder in Long-Term Drinking Rats: Behavioral and Electrophysiological Findings

Neuropsychopharmacology

Volumn 40, Issue , 2015, Pages 1130-1140

  Fredriksson, Ida ^a   Jayaram Lindström, Nitya ^a   Wirf, Malin ^a   Nylander, Erik ^a   Nyström, Erica ^a   Jardemark, Kent ^a   Steensland, Pia ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GUANFACINE; NALTREXONE; ALCOHOL; CENTRAL DEPRESSANT AGENT; DRUGS USED IN THE TREATMENT OF ADDICTION; GLUTAMIC ACID;

ALCOHOL CONSUMPTION; ALCOHOL USE DISORDER; ALCOHOL WITHDRAWAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRINKING BEHAVIOR; ELECTROPHYSIOLOGICAL PROCEDURES; IN VIVO STUDY; MEDIAL PREFRONTAL CORTEX; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RAT; ALCOHOLISM; ASSOCIATION; BEHAVIOR; DRUG EFFECT; FLUID INTAKE; GLUTAMATERGIC SYNAPSE; LONG TERM EXPOSURE; MALE; ALCOHOL-RELATED DISORDERS; ANIMAL; DECISION MAKING; DISEASE MODEL; DRUG EFFECTS; DRUG SEEKING BEHAVIOR; INSTRUMENTAL CONDITIONING; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PRECLINICAL STUDY; PREFRONTAL CORTEX; TISSUE CULTURE TECHNIQUE; TREATMENT OUTCOME; WISTAR RAT;

ALCOHOL DETERRENTS; ALCOHOL DRINKING; ALCOHOL-RELATED DISORDERS; ANIMALS; CENTRAL NERVOUS SYSTEM DEPRESSANTS; CHOICE BEHAVIOR; CONDITIONING, OPERANT; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUG-SEEKING BEHAVIOR; ETHANOL; GLUTAMIC ACID; GUANFACINE; MALE; NALTREXONE; PREFRONTAL CORTEX; PYRAMIDAL CELLS; RATS, WISTAR; TISSUE CULTURE TECHNIQUES; TREATMENT OUTCOME;

EID: 84925507494     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2014.294     Document Type: Article

References (44)

1. Anton RF, Oroszi G, O'Malley S, Couper D, Swift R, Pettinati H et al (2008). An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 65: 135-144.
2. Arnsten AF (2010). The use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder. Expert Rev Neurother 10: 1595-1605.
3. Arnsten AF (2011). Catecholamine influences on dorsolateral prefrontal cortical networks. Biol Psychiatry 69: e89-e99.
4. Arnsten AF, Jin LE (2014). Molecular influences on working memory circuits in dorsolateral prefrontal cortex. Prog Mol Biol Transl Sci 122: 211-231.
5. Arnsten AF, Steere JC, Hunt RD (1996). The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder. Arch Gen Psychiatry 53: 448-455.
6. Arvanov VL, Liang X, Schwartz J, Grossman S, Wang RY (1997). Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J Pharmacol Exp Ther 283: 226-234.
7. Arvanov VL, Wang RY (1998). M100907, a selective 5-HT2A receptor antagonist and a potential antipsychotic drug, facilitates N-methyl-D-aspartate-receptor mediated neurotransmission in the rat medial prefrontal cortical neurons in vitro. Neuropsychopharmacology 18: 197-209.
8. Avery RA, Franowicz JS, Studholme C, van Dyck CH, Arnsten AF (2000). The alpha-2A-adrenoceptor agonist, guanfacine, increases regional cerebral blood flow in dorsolateral prefrontal cortex of monkeys performing a spatial working memory task. Neuropsychopharmacology 23: 240-249.
9. Fernando AB, Economidou D, Theobald DE, Zou MF, Newman AH, Spoelder M et al (2012). Modulation of high impulsivity and attentional performance in rats by selective direct and indirect dopaminergic and noradrenergic receptor agonists. Psychopharmacology (Berl) 219: 341-352.
10. Fox HC, Morgan PT, Sinha R (2014). Sex differences in guanfacine effects on drug craving and stress arousal in cocaine-dependent individuals. Neuropsychopharmacology 39: 1527-1537.
11. Fox HC, Seo D, Tuit K, Hansen J, Kimmerling A, Morgan PT et al (2012). Guanfacine effects on stress, drug craving and prefrontal activation in cocaine dependent individuals: preliminary findings. J Psychopharmacol 26: 958-972.
12. Gamo NJ, Arnsten AF (2011). Molecular modulation of prefrontal cortex: rational development of treatments for psychiatric disorders. Behav Neurosci 125: 282-296.
13. Goddard AW, Ball SG, Martinez J, Robinson MJ, Yang CR, Russell JM et al (2010). Current perspectives of the roles of the central norepinephrine system in anxiety and depression. Depress Anxiety 27: 339-350.
14. Goldstein RZ, Volkow ND (2011). Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. Nat Rev Neurosci 12: 652-669.
15. Holmes A, Spanagel R, Krystal JH (2013). Glutamatergic targets for new alcohol medications. Psychopharmacology (Berl) 229: 539-554.
16. Konradsson A, Marcus MM, Hertel P, Svensson TH, Jardemark KE (2006). Inhibition of the glycine transporter GlyT-1 potentiates the effect of risperidone, but not clozapine, on glutamatergic transmission in the rat medial prefrontal cortex. Synapse 60: 102-108.
17. Le AD, Funk D, Juzytsch W, Coen K, Navarre BM, Cifani C et al (2011). Effect of prazosin and guanfacine on stress-induced reinstatement of alcohol and food seeking in rats. Psychopharmacology 218: 89-99.
18. Litten RZ, Ryan ML, Fertig JB, Falk DE, Johnson B, Dunn KE et al (2013). A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. J Addict Med 7: 277-286.
19. Marrs W, Kuperman J, Avedian T, Roth RH, Jentsch JD (2005). Alpha-2 adrenoceptor activation inhibits phencyclidine-induced deficits of spatial working memory in rats. Neuropsychopharmacology 30: 1500-1510.
20. McKee SA, Harrison EL, O'Malley SS, Krishnan-Sarin S, Shi J, Tetrault JM et al (2009). Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biol Psychiatry 66: 185-190.
21. McKinzie DL, Nowak KL, Yorger L, McBride WJ, Murphy JM, Lumeng L et al (1998). The alcohol deprivation effect in the alcohol-preferring P rat under free-drinking and operant access conditions. Alcohol Clin Exp Res 22: 1170-1176.
22. Mitchell JM, Teague CH, Kayser AS, Bartlett SE, Fields HL (2012). Varenicline decreases alcohol consumption in heavy-drinking smokers. Psychopharmacology 223: 299-306.
23. Opitz K (1990). The effect of clonidine and related substances on voluntary ethanol consumption in rats. Drug Alcohol Depend 25: 43-48.
24. Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR et al (2003). A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28: 1546-1552.
25. Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J (2009). Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 373: 2223-2233.
26. Riga D, Schmitz LJ, van der Harst JE, van Mourik Y, Hoogendijk WJ, Smit AB et al (2014). A sustained depressive state promotes a guanfacine reversible susceptibility to alcohol seeking in rats. Neuropsychopharmacology 39: 1115-1124.
27. Sallee FR, Eaton K (2010). Guanfacine extended-release for attention-deficit/hyperactivity disorder (ADHD). Expert Opin Pharmacother 11: 2549-2556.
28. Sallee FR, Lyne A, Wigal T, McGough JJ (2009a). Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 19: 215-226.
29. Sallee FR, McGough J, Wigal T, Donahue J, Lyne A, Biederman J (2009b). Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 48: 155-165.
30. Sanchis-Segura C, Spanagel R (2006). Behavioural assessment of drug reinforcement and addictive features in rodents: an overview. Addict Biol 11: 2-38.
31. Sica DA (2007). Centrally acting antihypertensive agents: an update. J Clin Hypertens (Greenwich) 9: 399-405.
32. Simms JA, Bito-Onon JJ, Chatterjee S, Bartlett SE (2010). Long- Evans rats acquire operant self-administration of 20% ethanol without sucrose fading. Neuropsychopharmacology 35: 1453-1463.
33. Simms JA, Steensland P, Medina B, Abernathy KE, Chandler LJ, Wise R et al (2008). Intermittent access to 20% ethanol induces high ethanol consumption in Long-Evans and Wistar rats. Alcohol Clin Exp Res 32: 1816-1823.
34. Sinclair JD, Tiihonen K (1988). Lack of alcohol-deprivation effect in AA rats. Alcohol 5 : 85-87.
35. Smith RJ, Aston-Jones G (2011). alpha(2) Adrenergic and imidazoline receptor agonists prevent cue-induced cocaine seeking. Biol Psychiatry 70: 712-719.
36. Spanagel R, Holter SM (2000). Pharmacological validation of a new animal model of alcoholism. J Neural Transm 107: 669-680.
37. Steensland P, Fredriksson I, Holst S, Feltmann K, Franck J, Schilstrom B et al (2012). The monoamine stabilizer (-)- OSU6162 attenuates voluntary ethanol intake and ethanol-induced dopamine output in nucleus accumbens. Biol Psychiatry 72: 823-831.
38. Steensland P, Simms JA, Holgate J, Richards JK, Bartlett SE (2007). Varenicline, an {alpha}4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci USA 104: 12518-12523.
39. Steensland P, Simms JA, Nielsen CK, Holgate J, Bito-Onon JJ, Bartlett SE (2010). The neurokinin 1 receptor antagonist, ezlopitant, reduces appetitive responding for sucrose and ethanol. PLoS One 5: e12527.
40. Taylor FB, Russo J (2001). Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 21: 223-228.
41. van Zwieten PA (1999). The renaissance of centrally acting antihypertensive drugs. J Hypertens Suppl 17: S15-S21.
42. Vengeliene V, Siegmund S, Singer MV, Sinclair JD, Li TK, Spanagel R (2003). A comparative study on alcohol-preferring rat lines: effects of deprivation and stress phases on voluntary alcohol intake. Alcohol Clin Exp Res 27: 1048-1054.
43. Wang M, Ramos BP, Paspalas CD, Shu Y, Simen A, Duque A et al (2007). Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell 129: 397-410.
44. Wise RA (1973). Voluntary ethanol intake in rats following exposure to ethanol on various schedules. Psychopharmacology (Berl) 29: 203-210.